Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens

Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one retrospective study were used to determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would be associated with dose‐limiting toxicity (DLT) in colon can...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Med
Main Authors: Ali, Raafi, Baracos, Vickie E., Sawyer, Michael B., Bianchi, Laurent, Roberts, Sarah, Assenat, Eric, Mollevi, Caroline, Senesse, Pierre
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2016
Teme:
Clinical Cancer Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4831278/
https://ncbi.nlm.nih.gov/pubmed/26814378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.621
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki